ATC code A02

ATC codes
A Alimentary tract and metabolism
A01 Stomatological preparations
A02 Drugs for acid related disorders
A03 Drugs for functional gastrointestinal disorders
A04 Antiemetics and antinauseants
A05 Bile and liver therapy
A06 Drugs for constipation
A07 Antidiarrheals, intestinal anti-inflammatory/anti-infective agents
A08 Antiobesity preparations, excluding diet products
A09 Digestives, including enzymes
A10 Drugs used in diabetes
A11 Vitamins
A12 Mineral supplements
A13 Tonics
A14 Anabolic agents for systemic use
A15 Appetite stimulants
A16 Other alimentary tract and metabolism products

ATC code A02 Drugs for acid related disorders is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the WHO for the classification of drugs and other medical products. Subgroup A02 is part of the anatomical group A Alimentary tract and metabolism.[1]

Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QA02.[2]

National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.

A02A Antacids

A02AA Magnesium compounds

A02AA01 Magnesium carbonate
A02AA02 Magnesium oxide
A02AA03 Magnesium peroxide
A02AA04 Magnesium hydroxide
A02AA05 Magnesium silicate
A02AA10 Combinations

A02AB Aluminium compounds

A02AB01 Aluminium hydroxide
A02AB02 Algeldrate
A02AB03 Aluminium phosphate
A02AB04 Dihydroxialumini sodium carbonate
A02AB05 Aluminium acetoacetate
A02AB06 Aloglutamol
A02AB07 Aluminium glycinate
A02AB10 Combinations

A02AC Calcium compounds

A02AC01 Calcium carbonate
A02AC02 Calcium silicate
A02AC10 Combinations

A02AD Combinations and complexes of aluminium, calcium and magnesium compounds

A02AD01 Ordinary salt combinations
A02AD02 Magaldrate
A02AD03 Almagate
A02AD04 Hydrotalcite
A02AD05 Almasilate

A02AF Antacids with antiflatulents

A02AF01 Magaldrate and antiflatulents
A02AF02 Ordinary salt combinations and antiflatulents

A02B Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)

A02BA H2-receptor antagonists

A02BA01 Cimetidine
A02BA02 Ranitidine
A02BA03 Famotidine
A02BA04 Nizatidine
A02BA05 Niperotidine
A02BA06 Roxatidine
A02BA07 Ranitidine bismuth citrate
A02BA08 Lafutidine
A02BA51 Cimetidine, combinations
A02BA53 Famotidine, combinations

A02BB Prostaglandins

A02BB01 Misoprostol
A02BB02 Enprostil

A02BC Proton pump inhibitors

A02BC01 Omeprazole
A02BC02 Pantoprazole
A02BC03 Lansoprazole
A02BC04 Rabeprazole
A02BC05 Esomeprazole
A02BC06 Dexlansoprazole
A02BC07 Dexrabeprazole
A02BC53 Lansoprazole, combinations
A02BC54 Rabeprazole, combinations

A02BD Combinations for eradication of Helicobacter pylori

A02BD01 Omeprazole, amoxicillin and metronidazole
A02BD02 Lansoprazole, tetracycline and metronidazole
A02BD03 Lansoprazole, amoxicillin and metronidazole
A02BD04 Pantoprazole, amoxicillin and clarithromycin
A02BD05 Omeprazole, amoxicillin and clarithromycin
A02BD06 Esomeprazole, amoxicillin and clarithromycin
A02BD07 Lansoprazole, amoxicillin and clarithromycin
A02BD08 Bismuth subcitrate, tetracycline and metronidazole
A02BD09 Lansoprazole, clarithromycin and tinidazole
A02BD10 Lansoprazole, amoxicillin and levofloxacin
A02BD11 Pantoprazole, amoxicillin, clarithromycin and metronidazole

A02BX Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)

A02BX01 Carbenoxolone
A02BX02 Sucralfate
A02BX03 Pirenzepine
A02BX04 Methiosulfonium chloride
A02BX05 Bismuth subcitrate
A02BX06 Proglumide
A02BX07 Gefarnate
A02BX08 Sulglicotide
A02BX09 Acetoxolone
A02BX10 Zolimidine
A02BX11 Troxipide
A02BX12 Bismuth subnitrate
A02BX13 Alginic acid
A02BX51 Carbenoxolone, combinations excluding psycholeptics
A02BX71 Carbenoxolone, combinations with psycholeptics
A02BX77 Gefarnate, combinations with psycholeptics

A02X Other drugs for acid related disorders

Empty

References

  1. "ATC/DDD Index 2016: code A02". WHO Collaborating Centre for Drug Statistics Methodology.
  2. "ATCvet Index 2016: code QA02". WHO Collaborating Centre for Drug Statistics Methodology.
This article is issued from Wikipedia - version of the 1/4/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.